HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 29, 2013
Insider Transaction Report
Form 4
ALLEN PETER M
Chief Marketing Officer
Transactions
- Disposition to Issuer
Common Stock
2013-10-28$39.55/sh−417$16,493→ 29,382 total - Award
Non-Qualified Stock Option (right to buy)
2013-10-23+30,201→ 30,201 totalExercise: $41.66From: 2014-10-23Exp: 2019-10-23→ Common Stock (30,201 underlying) - Disposition to Issuer
Common Stock
2013-10-27$39.55/sh−238$9,413→ 29,799 total - Disposition to Issuer
Common Stock
2013-10-28$39.55/sh−432$17,086→ 28,950 total
Holdings
- 30,494
Non-Qualified Stock Option (right to buy)
Exercise: $27.27From: 2009-10-22Exp: 2015-10-22→ Common Stock (30,494 underlying) - 30,776
Non-Qualified Stock Option (right to buy)
Exercise: $27.50From: 2011-10-27Exp: 2017-10-27→ Common Stock (30,776 underlying) - 30,000
Non-Qualified Stock Option (right to buy)
Exercise: $13.05From: 2005-05-05Exp: 2014-05-05→ Common Stock (30,000 underlying) - 31,340
Non-Qualified Stock Option (right to buy)
Exercise: $26.47From: 2010-10-27Exp: 2016-10-27→ Common Stock (31,340 underlying) - 30,740
Non-Qualified Stock Option (right to buy)
Exercise: $30.67From: 2012-10-25Exp: 2018-10-25→ Common Stock (30,740 underlying) - 32,192
Non-Qualified Stock Option (right to buy)
Exercise: $39.05From: 2013-10-24Exp: 2019-10-24→ Common Stock (32,192 underlying) - 36,426
Non-Qualified Stock Option (right to buy)
Exercise: $25.54From: 2008-10-24Exp: 2014-10-24→ Common Stock (36,426 underlying) - 25,000
Performance Shares
Exercise: $0.00From: 2017-03-31Exp: 2017-12-31→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]Pursuant to a 10b5-1 Plan to cover tax liability for released shares.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).